Olivier EDWARDS

Olivier Edwards: is a lawyer who advises emerging companies and venture capital funds on investment, merger & acquisition matters with an emphasis on cross-border deals.

Olivier has been recognized in Chambers & Partners where he has been described by his clients as “a very senior lawyer with vast experience in the merger and acquisition process”, "a talented lawyer and leading figure.“

He is a top-tier venture capital practitioner renowned for his fund-raising prowess and is often called the “godfather" of French venture law. He recently integrated the Legal 500 Hall of fame in Venture Capital for receiving "..constant praise by their clients for continued excellence.

The Hall of Fame highlights, to clients, the law firm partners who are at the pinnacle of the profession." (Legal 500) He also has been appointed Senior State People by Chambers in 2018 a qualification wich is seldom granted. With a great experience on cross-border merger and acquisitions deals, and joint-venture operations, Oliver has worked with key players of the tech market such as eBay, SoftBank, Accel Ventures, Balyo, Biom'Up, Aledia, Greenerwave, Pegascy, Highllife….

Olivier is involved in pro-bono activities. He is a co-founder / member of CroissancePlus and PME Finance, two non-profit organizations dedicated to fast-growth companies. Before joining Orrick as a Senior Counsel, Olivier was a partner at Gide Loyrette Nouel and was the Head of European Venture department at Morgan Lewis law firm.

PEGASCY governance

Founders

MD, phD
 

Jean-harles Soria: is Amgen’s senior vice president of Oncology within Global Development. Soria joins Amgen from Institut Gustave Roussy

Jean-Charles

SORIA

Chief Executive Officer
 

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI). He was recently General Director of the Institut Claudius Regaud in Toulouse.

Jean-Pierre

ARMAND

MD, phD
 

Fabrice André: Director of Research at Gustave Roussy since February 2020, Prof. Fabrice André coordinates the Institute's medical-scientific research programs, in conjunction with the Medical Director.

Fabrice

ANDRÉ

 

MD, phD
 

Aurelie Marabelle: MD, PhD, is a Senior Medical Oncologist in the Drug Development Department (DITEP), a group leader in Prof Laurence Zitvogel’s lab (INSERM U1015)

Aurélien

MARABELLE

MBA
 

Sébastien Bazin: After five years working in several financial positions in New York, San Francisco and London

Sébastien

BAZIN

MBA
 

Thierry Bruhat: he spent more than 20 years in supporting innovation projects and policies based on cooperation between companies, research

Thierry

BRUHAT

Board

Chairman
 

Jean-Pierre Armand MD, MSc, is certified in Medical Oncology (University of Toulouse III and Paris XI). He was recently General Director of the Institut Claudius Regaud in Toulouse.

Jean-Pierre

ARMAND

Censor
 

Sébastien Bazin: After five years working in several financial positions in New York, San Francisco and London

Sebastien

BAZIN

Directors
 

Fabrice Barlesi: As a specialist in lung cancer, precision medicine and cancer immunology

Fabrice

BARLESI

Directors
 

Olivier Edwards: is a lawyer who advises emerging companies and venture capital funds on investment, merger & acquisition matters with an emphasis on cross-border deals.

Olivier

EDWARDS

COO/CFO
 

Jean-Paul Alves, BSc in Economy, Graduated from EM Lyon and Post Graduated in Managerial Accounting, Chartered Accounting and Tax, joined Pegascy in 2020 as Chief Financial Officer.

Jean-Paul

ALVES